John M. Gansner

2.1k citations

28 papers · 872 indexed · h-index 13

Impact in

Nephrology top 5%
- Renal Diseases and Glomerulopathies
Hematology top 5%
- Platelet Disorders and Treatments
- Blood groups and transfusion

Papers in

Hematology 7
- Blood groups and transfusion 4
- Platelet Disorders and Treatments 3
Cell Biology 7

Co-authors: Jonathan D. Gitlin Richard M. Kaufman Robert S. Makar Ayad Hamdan Lynne Uhl Stephen W. Waldo Ang Li Andrew M. Brunner
Journals: Transfusion (3 papers)Developmental Dynamics (3 papers)Journal of Hepatology (2 papers)Kidney International Reports (2 papers)Frontiers in Pediatrics (1 paper)
Partner nations: United States Israel France

In The Last Decade

John M. Gansner

26 papers receiving 852 citations

Peers

Countries citing papers authored by John M. Gansner

Since Specialization

Citations

This map shows the geographic impact of John M. Gansner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Gansner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Gansner more than expected).

Fields of papers citing papers by John M. Gansner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John M. Gansner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Gansner. The network helps show where John M. Gansner may publish in the future.

Co-authors

The 25 scholars most cited alongside John M. Gansner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John M. Gansner Line = papers co-authored together John M. Gansner links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Long-term lumasiran therapy final results from a Phase 2 open-label extension study in primary hyperoxaluria Nephrology Dialysis Transplantation ·Yaacov Frishberg, Jaap W. Groothoff, Sally‐Anne Hulton, Jérôme Harambat, Julien Hogan, Anne‐Laure Sellier‐Leclerc, Wesley Hayes, Martin Coenen, Richard E. Willey, John M. Gansner, Daniella Magen	2025	0
2	Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis Journal of Hepatology ·Arun J. Sanyal, Jörg Täubel, Prajakta Badri, Sarah Bond, Nune Makarova, Weizhi Zhao, Swati Duggal, Farshad Kajbaf, Benjamin A. Olenchock, John M. Gansner	2025	2
3	Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective Study Kidney Medicine ·John C. Lieske, Jaap W. Groothoff, Yaacov Frishberg, Sander F. Garrelfs, Dawn S. Milliner, Daniella Magen, Anne‐Laure Sellier‐Leclerc, Hadas Shasha‐Lavsky, Sevcan A. Bakkaloğlu, Sandrine Lemoine, Daniel G. Fuster, Arnaud Devresse, Ruth Cytter-Kuint, Farshad Kajbaf, W. J. Du, John M. Gansner	2025	0
4	Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial Frontiers in Pediatrics ·Yaacov Frishberg, Wesley Hayes, Hadas Shasha‐Lavsky, David J. Sas, Mini Michael, Anne‐Laure Sellier‐Leclerc, Julien Hogan, Richard E. Willey, John M. Gansner, Daniella Magen	2024	1
5	Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial Kidney International Reports ·Jeffrey M. Saland, John C. Lieske, Jaap W. Groothoff, Yaacov Frishberg, Hadas Shasha‐Lavsky, Daniella Magen, Shabbir H. Moochhala, Eva Šimková, Martin Coenen, Wesley Hayes, Julien Hogan, Anne‐Laure Sellier‐Leclerc, Richard E. Willey, John M. Gansner, Sally‐Anne Hulton	2024	7
6	Lumasiran for Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 24-Month Analysis of the Phase 3 ILLUMINATE-C Trial Journal of the American Society of Nephrology ·John C. Lieske, Daniella Magen, Anne-Laure A. Sellier-Leclerc, Hadas Shasha‐Lavsky, Eva Šimková, Arnaud Devresse, Mini Michael, Yaacov Frishberg, Sevcan A. Bakkaloğlu, Chebl Mourani, Rola Saqan, Richard Singer, Isabella Guzzo, Nune Makarova, Richard G. Willey, Cristin Kaspar, John M. Gansner, Jaap W. Groothoff	2023	1
7	Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial Pediatric Nephrology ·Wesley Hayes, David J. Sas, Daniella Magen, Hadas Shasha‐Lavsky, Mini Michael, Anne‐Laure Sellier‐Leclerc, Julien Hogan, Taylor Ngo, Marianne T. Sweetser, John M. Gansner, Tracy L. McGregor, Yaacov Frishberg	2022	30
8	Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial American Journal of Kidney Diseases ·Mini Michael, Jaap W. Groothoff, Hadas Shasha‐Lavsky, John C. Lieske, Yaacov Frishberg, Eva Šimková, Anne‐Laure Sellier‐Leclerc, Arnaud Devresse, Fitsum Guebre‐Egziabher, Sevcan A. Bakkaloğlu, Chebl Mourani, Rola Saqan, Richard Singer, Richard E. Willey, Bahru Habtemariam, John M. Gansner, Ishir Bhan, Tracy L. McGregor, Daniella Magen	2022	50
9	Frequent platelet donation is associated with lymphopenia and risk of infections: A nationwide cohort study Transfusion ·Jingcheng Zhao, Erin E. Gabriel, Rut Norda, Petter Höglund, Lindsey R. Baden, Beatrice Diedrich, Per Marits, Sara Lind Enoksson, John M. Gansner, Richard M. Kaufman, Paul W. Dickman, Gustaf Edgren	2020	9
10	Severe CD4+ T‐cell lymphopenia is not observed in frequent plateletpheresis donors collected on the Fenwal Amicus Transfusion ·John M. Gansner, Mona Papari, J. Goldstein, Rachel A. Gaufberg, Donna Neuberg, Robert S. Makar, Richard M. Kaufman	2019	3
11	The rheumatology/hematology interface: CAPS and MAS diagnosis and management Hematology ·John M. Gansner, Nancy Berliner	2018	7
12	Protection from UV light is an evolutionarily conserved feature of the haematopoietic niche Nature ·Friedrich Kapp, Julie R. Perlin, Elliott J. Hagedorn, John M. Gansner, Daniel Schwarz, Lauren A. O’Connell, Nicholas S. Johnson, Chris T. Amemiya, David E. Fisher, Ute Wölfle, Eirini Trompouki, Charlotte M. Niemeyer, Wolfgang Driever, Leonard I. Zon	2018	58
13	Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study The Lancet Haematology ·Pavan K. Bendapudi, Shelley Hurwitz, Ashley Michelle Fry, Marisa B. Marques, Stephen W. Waldo, Ang Li, Lova Sun, Vivek Upadhyay, Ayad Hamdan, Andrew M. Brunner, John M. Gansner, Srinivas R. Viswanathan, Richard M. Kaufman, Lynne Uhl, Christopher P. Stowell, Sunny Dzik, Robert S. Makar	2017	314
14	Transplantation in zebrafish Methods in cell biology ·John M. Gansner, Michelle Dang, Michelle Ammerman, Leonard I. Zon	2016	26
15	Telomeres in lung disease Translational research ·John M. Gansner, Iván O. Rosas	2013	30
16	Lysyl oxidase-like 3b is critical for cartilage maturation during zebrafish craniofacial development Matrix Biology ·Antonius L. van Boxtel, John M. Gansner, Henk W. J. Hakvoort, Heather D. Snell, Juliette Legler, Jonathan D. Gitlin	2011	20
17	Essential role for fibrillin‐2 in zebrafish notochord and vascular morphogenesis Developmental Dynamics ·John M. Gansner, Erik Madsen, Robert P. Mecham, Jonathan D. Gitlin	2008	33
18	Essential role for the alpha 1 chain of type VIII collagen in Zebrafish notochord formation Developmental Dynamics ·John M. Gansner, Jonathan D. Gitlin	2008	42
19	Essential role of lysyl oxidases in notochord development Developmental Biology ·John M. Gansner, Bryce A. Mendelsohn, Keith A. Hultman, Stephen L. Johnson, Jonathan D. Gitlin	2007	74
20	Chemical genetics suggests a critical role for lysyl oxidase in zebrafish notochord morphogenesis Molecular BioSystems ·Carrie L. Anderson, Stephen J. Bartlett, John M. Gansner, Duncan Wilson, Ling He, Jonathan D. Gitlin, Robert N. Kelsh, James Dowden	2006	56

About John M. Gansner

John M. Gansner is a scholar working on Hematology, Cell Biology, Urology, Pediatrics, Perinatology and Child Health and Management of Technology and Innovation, having authored 28 papers that have together received 872 indexed citations. Recurring topics across this work include Kidney Stones and Urolithiasis Treatments (8 papers), Biomedical Research and Pathophysiology (5 papers), Kruppel-like factors research (4 papers), Connective tissue disorders research (4 papers), Blood groups and transfusion (4 papers), Neonatal Health and Biochemistry (3 papers), Platelet Disorders and Treatments (3 papers) and Microbial metabolism and enzyme function (3 papers). The work is most often cited by research in Nephrology (168 citations), Hematology (201 citations), Immunology (344 citations), Transplantation (36 citations) and Genetics (120 citations). John M. Gansner has collaborated with scholars based in United States, Israel and France. Frequent co-authors include Jonathan D. Gitlin, Richard M. Kaufman, Robert S. Makar, Ayad Hamdan, Lynne Uhl, Stephen W. Waldo, Ang Li, Andrew M. Brunner, Leonard I. Zon and Shelley Hurwitz. Their work appears in journals such as Transfusion, Developmental Dynamics, Journal of Hepatology, Kidney International Reports and Frontiers in Pediatrics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact